Social media

At ICON we believe exceptional careers are built through purpose, leadership and local impact. In our latest blog, we shine a light on Karen Hahn’s leadership as Senior Director of Project Operations & Site Head in Mexic...

ICON is pleased to join industry leaders #DPHARM2025, taking place 16 - 17 September at the Loews Philadelphia Hotel. Visit us at booth #305 to connect with our experts and learn how ICON’s clinical, consulting, and com...

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

In the fast-paced world of pharma, making informed decisions starts with understanding the evidence. But with research output growing exponentially, how do you keep up? Our new whitepaper, “Demystifying the SLR: ‘S’ Sta...

Antibody-drug conjugates (ADCs) represent a growing class of targeted therapies, but their pharmacokinetic assessment presents unique challenges due to structural complexity, multiple analytes, and the need for diverse a...

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for interactions with both the MHRA and the National Institute for Health and Care Excellence (NICE). These ...

When commercialising a multi-indication drug, a narrow first launch strategy targets high-value populations for premium pricing but may slow accumulation of real world evidence. Understand these trade-offs in our arti...

Medical writing teams play a central role in regulatory submissions, but success depends on more than writing skill alone. In this IBI article, our experts explore how planning, leadership and collaboration support hig...

Struggling to keep up with the explosion of life sciences research? Systematic literature reviews (SLRs) are your key to navigating the noise with clarity and rigor. Download our latest whitepaper to learn: - How to co...

From complexity to clarity. See how ICON’s blended delivery model provides flexible, scalable solutions to suit or partners’ evolving clinical needs. Explore real results in our blended solutions case studies: https://o...

Preparing clinical data for submission to both the FDA and PMDA can be demanding. But with shared expectations and overlapping standards, there is a clear opportunity to streamline the process. Our latest whitepaper offe...

Susie McEvoy's path at ICON illustrates what it means to grow with purpose. Since joining as an HR Project Analyst in 2013, Susie has pursued every opportunity - from pioneering new roles to seeking mentorship, ultimatel...